Fish oil’s role in ADHD treatment remains modest and requires personalised approaches, recent evidence suggests

Recent comprehensive reviews indicate that while fish oil may offer modest benefits for some children with ADHD, it should be regarded as an adjunct, not a replacement for established therapies, with effectiveness dependent on individual omega-3 levels and treatment duration.

Fish oil may still appeal to families looking for a low-risk add-on for attention deficit hyperactivity disorder, but the best recent evidence suggests it should be treated as exactly that: an add-on, not a substitute for established care. A 2023 meta-analysis of randomised controlled trials found no statistically significant overall improvement in core ADHD symptoms from omega-3 supplements compared with placebo, although it did identify a small benefit in studies where treatment continued for at least four months.

That review, published in European Neuropsychopharmacology, drew together 22 trials involving 1,789 participants and tried to explain why earlier studies had pointed in different directions. Its authors highlighted differences in trial length, the make-up of supplements and the dose of eicosapentaenoic acid, or EPA, one of the two omega-3 fats most often studied alongside docosahexaenoic acid, or DHA. The broad result was underwhelming, but the longer-duration subgroup looked more promising, suggesting that time on treatment may matter if any effect is to emerge at all.

One reason fish oil has remained in the ADHD conversation is a Taiwan-UK trial that suggested the response may depend heavily on who is taking it. In that 12-week randomised study, 92 children and teenagers aged six to 18 were given a high-dose EPA supplement or a placebo. Researchers found gains in focused attention and vigilance among those with the lowest blood EPA levels at the outset, while children whose EPA levels were already normal or high did not show the same benefit. The same study also reported a warning sign that is often lost in simplified accounts: among children who started with high EPA levels, supplementation appeared to worsen impulsivity symptoms.

The researchers behind that trial argued for a more tailored approach rather than blanket use. Jane Chang of King’s College London said the findings suggested fish oil could perform as well as conventional drug treatment for attention in children who were omega-3 deficient, while Carmine Pariante said the supplements “only worked in children that had lower levels of EPA in their blood”. The group also noted that the study was carried out in Taiwan, where fish consumption is typically higher than in North America or much of Europe, raising the possibility that baseline diet may shape who benefits.

That personalised theory fits with a wider body of work. The US National Center for Complementary and Integrative Health says the evidence for omega-3 supplementation in children and adolescents with ADHD remains inconclusive: some randomised trials have shown modest benefits, but the supplements are less effective than stimulant medicines. The agency also notes preliminary signs that fish oil may work better than DHA alone and says adverse effects are usually minor, most often gastrointestinal.

A 2023 Cochrane review added a sharper note of caution. Looking across 37 trials with more than 2,374 participants, the review found low-certainty evidence that polyunsaturated fatty acids might improve ADHD symptoms in the medium term, but high-certainty evidence that they made no difference to total parent-rated ADHD symptoms. It also found no meaningful difference in inattention or hyperactivity/impulsivity between supplement and placebo groups. That matters because parent ratings are among the measures most often used to judge whether a treatment is changing daily life rather than shifting a narrower test result.

The American Academy of Pediatrics came to a similar conclusion when it reviewed the wider treatment landscape in 2024. Its systematic review, published in Pediatrics, examined 39 nutrition and supplement studies and said no specific supplement, including omega-3, consistently improved outcomes. For omega-3 in particular, the review described the evidence as low strength, with effect estimates clustered close to no benefit. In other words, even when fish oil is examined alongside other non-drug interventions, it does not stand out as a reliably effective treatment.

Older research helps explain why the idea has nevertheless proved durable. A 2018 systematic review and meta-analysis in Neuropsychopharmacology combined clinical trials with biological studies and found some evidence that children and adolescents with ADHD had lower omega-3 levels than their peers. It also reviewed eight supplementation studies covering 628 participants and found signs of small improvements in symptoms and cognitive performance, with higher EPA doses appearing more favourable than lower ones. Those findings helped set the agenda for later work by pointing researchers towards blood omega-3 status, especially EPA, as a possible marker of who might respond.

Taken together, the evidence leaves fish oil in a narrow but still plausible role. It may offer a modest benefit for some children, particularly over longer use or where omega-3 levels are low, and its side-effect profile is generally milder than that of many medicines. But the more comprehensive reviews do not support treating it as the nutritional equivalent of standard ADHD therapy. For clinicians and parents, the most defensible reading is that fish oil is a possible adjunct for selected patients, not a replacement for proven treatment and not a universal answer.